The first two days of the J.P. Morgan Healthcare Conference are in the books, and attendees are now pushing through to finish ...
AbbVie continues to project low single-digit growth through 2030 as it expands its immunology franchise and makes a major ...
Today's Research Daily features new research reports on 16 major stocks, including AbbVie Inc. (ABBV), Intel Corp. (INTC) and ...
The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.
Both Skyrizi and its cousin Rinvoq have landed in the annual top three, in varying positions, since 2022. That was once again the case in 2025, when Skyrizi retained its place at the top and Rinvoq ...
GlobalData on MSN
Lynk’s selective JAK inhibitor claims Phase III RA win
Lynk’s zemprocitinib commercial partner, Simcere, will now continue the JAK inhibitor’s development across China in RA.
Abivax (ABVX) stays a Buy as obefazimod UC data fuels multi‑billion potential; 2026 Phase 3/NDA catalysts loom and M&A ...
Ranked by Metro square feet broken ground on, 2023-2025 Ranked by 2025 Central Ohio remodeling sales volume Showcase your company news with guaranteed exposure both in print and online Get ready for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback